Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Valneva SE Sponsored ADR (VALN : NSDQ)

• Company Description    Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France. Number of Employees: 713

• Price / Volume Information    Yesterday's Closing Price: $8.94 Daily Weekly Monthly 20 Day Moving Average: 127,130 shares Shares Outstanding: 85.93 (millions) Market Capitalization: $768.19 (millions) Beta: 1.79 52 Week High: $12.25 52 Week Low: $3.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.61% -16.11% 12 Week 56.29% 41.97% Year To Date 104.48% 87.47%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6 rue Alain Bombard - Saint-Herblain,I0 44800 FRA ph: 33-2-28-07-37-10 fax: - investors@valneva.com http://www.valneva.com

• General Corporate Information    Officers Thomas Lingelbach - Chief Executive Officer;President and Director Anne-Marie Graffin - Chair of the Board of Directors Vincent Dequenne - Chief Operating Officer Peter Buhler - Chief Financial Officer Kendra Wergin - General Counsel and Corporate Secretary Peer Information Valneva SE Sponsored ADR (BJCT) Valneva SE Sponsored ADR (CADMQ) Valneva SE Sponsored ADR (APNO) Valneva SE Sponsored ADR (UPDC) Valneva SE Sponsored ADR (IMTIQ) Valneva SE Sponsored ADR (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 92025Y103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 85.93 Most Recent Split Date: (:1) Beta: 1.79 Market Capitalization: $768.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.12 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.59 Price/Cash Flow: 91.50 Price / Sales: 3.60 EPS Growth vs. Year Ago Period: 56.76% vs. Previous Quarter: -23.08% Sales Growth vs. Year Ago Period: 33.85% vs. Previous Quarter: 5.88% ROE 06/30/25 - -34.78 03/31/25 - -43.05 12/31/24 - -6.01 ROA 06/30/25 - -13.43 03/31/25 - -16.23 12/31/24 - -2.28 Current Ratio 06/30/25 - 2.27 03/31/25 - 2.70 12/31/24 - 2.61 Quick Ratio 06/30/25 - 1.77 03/31/25 - 2.12 12/31/24 - 2.14 Operating Margin 06/30/25 - -33.87 03/31/25 - -43.08 12/31/24 - -6.72 Net Margin 06/30/25 - -33.87 03/31/25 - -43.08 12/31/24 - -6.72 Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -6.77 Book Value 06/30/25 - 2.49 03/31/25 - 2.21 12/31/24 - 2.41 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - 1.88 Debt-to-Equity 06/30/25 - 0.66 03/31/25 - 0.92 12/31/24 - 0.92 Debt-to-Capital 06/30/25 - 39.63 03/31/25 - 47.95 12/31/24 - 47.88

Powered by Zacks Investment Research ©